GlassScriptPhysician profile
Emily Kollmann
NPI 1326308842
$12,968.93
in general payments reported to CMS, 2019-2025
30 companies · $3,033 in 2025
The $3,033 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,579 · 2020: $865 · 2021: $1,045 · 2022: $1,986 · 2023: $2,083 · 2024: $2,378 · 2025: $3,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,485 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,485.08 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,375.07 | 2019-2025 | |
| Lilly USA, LLC | $1,554.23 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $978.95 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $962.84 | 2022-2025 | Sotyktu |
| Ucb, INC. | $926.45 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $870.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $852.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $735.87 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $637.87 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $487.51 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $404.14 | 2023-2025 | Zoryve |
| Incyte Corporation | $334.06 | 2021-2025 | Opzelura |
| Amgen INC. | $313.31 | 2021-2025 | Otezla |
| Galderma Laboratories, L.P. | $282.58 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $262.04 | 2020-2024 | Siliq, Jublia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $185.00 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $167.52 | 2019-2024 | |
| Genzyme Corporation | $137.56 | 2020-2024 | |
| Genentech USA, INC. | $129.62 | 2019-2022 | |
| Dermira, INC. | $78.39 | 2019-2020 | |
| Organon LLC | $63.37 | 2025 | Vtama |
| Kyowa Kirin, INC. | $42.03 | 2022-2023 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $34.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.34 | 2022-2024 | Spevigo |
| Dusa Pharmaceuticals, INC. | $32.16 | 2019 | |
| Krystal Biotech INC | $25.97 | 2025 | Vyjuvek |
| Encore Dermatology INC. | $20.55 | 2020 | |
| Sandoz INC. | $15.17 | 2025 | Hyrimoz |
| Almirall LLC | $13.18 | 2021 | |
| Celgene Corporation | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kollmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.